Microsoft: Analysts Anticipate Q4 Earnings Per Share Of $2.29

Microsoft (NASDAQ: MSFT) will be reporting its fiscal fourth quarter financials today after markets close. Analysts have a consensus $344 12-month price target on the company, via a total of 52 analysts, with 19 analysts having strong buy ratings. 30 analysts meanwhile have buy ratings and three analysts have hold ratings. The street high sits at a $426 price target, and the lowest target sits at $252.

24 analysts have revenue estimates for the fourth quarter. The mean revenue estimate between all 24 analysts is $52.39 billion; this number is flat year to date now. The highest revenue estimate is $52.9 billion, while the lowest is $51.74 billion.

Onto EBITDA estimates, there are currently only six analysts who have fourth-quarter EBITDA estimates. The mean is currently $25.1 billion, with this number having been revised downwards from $25.4 billion at the start of the year. Street high is a $25.34 billion EBITDA estimate and the lowest is $24.88 billion.

Analysts estimate that quarterly earnings per share will come in at $2.29, with this number being revised steadily down since the start of the year. Street high is $2.35, and the lowest estimate is $2.24 per share for the quarter.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to the organizations discussed. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Higher Gold Prices Are Changing What Counts as a Real Discovery | Mike Bennett – Altamira Gold

Why Silver Still Hasn’t Seen the Real Mania | Craig Hemke

Why Copper Needs a Much Higher Price to Fix the Supply Problem | Greg Ferron – PTX Metals

Recommended

Crossroads Gold Closes Rox-ex Acquisition, Adds Pambula and Club Terrace to Australian Pipeline

Goliath Resources Kicks Off Fully Funded 50,000 Metre Drill Program At Surebet

Related News

BMO Raises Jazz Pharmaceuticals Price Target To US$205

It was announced last week wednesday that Jazz Pharmaceuticals (NASDAQ: JAZZ) would be acquiring GW...

Monday, February 8, 2021, 10:40:00 AM

Canaccord Raises Price Target On Alimentation Couche-Tard After Mixed Quarter

Last week, Alimentation Couche-Tard Inc. (TSX: ATD.B) reported its fiscal first quarter financial results. The...

Monday, September 6, 2021, 02:23:00 PM

Canopy Growth: Analysts Anticipate Q1 Revenues Of $149 Million

Canopy Growth Corp (TSX: WEED) (NASDAQ: CGC) announced that they will be reporting their fiscal...

Tuesday, August 3, 2021, 03:28:00 PM

Enthusiast Gaming Sees Canaccord Reiterate $9.00 Price Target

On November 23rd, Enthusiast Gaming (TSX: EGLX) announced that they acquired Outplayed, Inc, the owners...

Saturday, November 27, 2021, 04:27:00 PM

Cresco Labs: Canaccord Drops Price Target To $16

On November 11th, Cresco Labs (CSE: CL) reported its third-quarter financial results. The company reported...

Saturday, November 13, 2021, 01:04:00 PM